For example, in NSCLC, combining anti-PD-1/PD-L1 with CAR-T cell therapy promotes the restoration of normal immune recognition function and maintains immune system homeostasis [438]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.